NCT00186095

Brief Summary

To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Dec 2000

Longer than P75 for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2000

Completed
4.8 years until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 16, 2005

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2006

Completed
Last Updated

June 23, 2022

Status Verified

June 1, 2022

First QC Date

September 13, 2005

Last Update Submit

June 16, 2022

Conditions

Amyloidosis

Keywords

Amyloidosisnonmyeloablativehematopoieticcell transplantation

Outcome Measures

Primary Outcomes (1)

  • Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Secondary Outcomes (3)

  • Toxicity of therapy

  • Changes in marrow and serum abnormalities

  • Improvement in end-organ function.

Interventions

autologous followed by nonmyeloablative allogeneic transplantPROCEDURE

Eligibility Criteria

AgeUp to 60 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • primary amyloidosis
  • adequate organ function
  • matched sibling donor

You may not qualify if:

  • evidence of multiple myeloma
  • HIV positive

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Amyloidosis

Condition Hierarchy (Ancestors)

Proteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Keith Stockerl-Goldstein, MD

    Stanford University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 16, 2005

Study Start

December 1, 2000

Study Completion

September 1, 2006

Last Updated

June 23, 2022

Record last verified: 2022-06